Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Firefly Neuroscience has developed and commercialized the FDA-cleared Brain Network Analytics (BNA™) platform, which uses AI to analyze EEG data for objective assessment of brain function. The technology is validated in real-world clinical settings for early detection and monitoring of neurological conditions such as dementia, depression, anxiety disorders, concussion, and ADHD. Recent research includes the discovery of a cognitive brain age biomarker for Alzheimer’s disease screening using their proprietary database. The company is actively partnering with pharmaceutical companies to support drug development through companion diagnostics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Firefly Neuroscience.